Uncategorized
Glaukos Corporation Announces First Quarter 2020 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2020. Key highlights include: Q1 2020 net sales of $55.3 million, compared to $54.0 million in Q1 2019. Glaucoma Q1 2020 net sales of $44.1 million, compared to $54.0 million in Q1 2019. Corneal H